Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06087913 · ClinicalTrials.gov registry record · Phase 1
Safety and PK Multi-dose Study of TAF/EVG Vaginal Insert
A Phase 1 study, sponsored by Eastern Virginia Medical School.
- Completed
- Registry status
- Phase 1
- Development phase
- 68
- Enrollment target
NCT06087913 is a Phase 1 study that has completed, run by Eastern Virginia Medical School. The registered enrollment target is 68 participants.
The verdict
NCT06087913, a Phase 1 study, has completed, sponsored by Eastern Virginia Medical School.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 68 participants
- Enrollment target
Study Summary
MATRIX-001 will examine the safety, PK, modeled PD, and acceptability of inserts containing the combination of TAF and EVG applied vaginally, daily for 3 days, then every other day for 14 days. The inserts are ultimately intended to be the basis of an event-driven, on-demand method for prevention of HIV and HSV sexual infection.
Interventions
- DRUG TAF/EVG vaginal insert
- DRUG Matching Placebo vaginal insert
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2023-11-08 |
| Est. Completion | 2024-12-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06087913
The ClinicalTrials.gov registry entry for NCT06087913 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eastern Virginia Medical School, which has 36 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which TAF/EVG vaginal insert is the first listed.
NCT06087913 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06087913 about?
NCT06087913 is a clinical study titled "Safety and PK Multi-dose Study of TAF/EVG Vaginal Insert". MATRIX-001 will examine the safety, PK, modeled PD, and acceptability of inserts containing the combination of TAF and EVG applied vaginally, daily for 3 days, then every other day for 14 days. The inserts are ultimately intended to be the basis of an event-driven, on-demand method for prevention of...
What is the current status of trial NCT06087913?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 68 participants. The study started on 2023-11-08. Estimated completion is 2024-12-02.
What interventions are being tested in trial NCT06087913?
The interventions under investigation include: TAF/EVG vaginal insert (DRUG), Matching Placebo vaginal insert (DRUG).
Who is sponsoring clinical trial NCT06087913?
This trial is sponsored by Eastern Virginia Medical School, which has 36 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.